Month: September 2020

– Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate– Company to host virtual KOL event to review data today at 8:00am ETREHOVOT, Israel and WILMINGTON, Del., Sept. 18, 2020 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) (Ayala or the Company), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced positive interim results from the ongoing Phase 2 ACCURACY clinical trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch-activating mutations in a mini oral presentation at the European Society for Medical Oncology...

NEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) — Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the commercial launch of the KidneyIntelX clinical test reporting platform within the Mount Sinai Health System (Mount Sinai) in New York City. KidneyIntelX risk assessment of progressive decline in kidney function or kidney failure, including education support for treating clinicians, is now commercially available for patients with early stage diabetic kidney disease (DKD). In addition to patient testing and risk assessment, a central component of this launch milestone is the physician education and support program developed in close collaboration...

CALGARY, Alberta, Sept. 18, 2020 (GLOBE NEWSWIRE) — The Board of Directors of Computer Modelling Group Ltd. (“CMG” or the “Company”) is pleased to announce the appointment of Kelly Tomyn as Interim Vice President, Finance and Chief Financial Officer of the Company effective September 21, 2020. Ms. Tomyn is assuming the role while CMG’s current Vice President, Finance and Chief Financial Officer, Sandra Balic, takes a parental leave of absence for a period of approximately 12 months.Ms. Tomyn is an experienced finance leader with over 25 years of experience in the oil and gas industry. She brings 18 years of diverse business experience serving in Chief Financial Officer roles with a focus on public companies and has a wide breadth of experience in all aspects of financial operations and business strategy. Ms. Tomyn is...

Successfully completed IPO in August 2020 raising $76.6 million in gross proceedsOn track to initiate planned new clinical trials in melanoma and head and neck cancerCAMBRIDGE, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced second quarter 2020 financial results and provided an update on recent progress.“This is an exciting time for our company as we rapidly develop CMP-001 across multiple tumor types in combination with checkpoint inhibitors,” said Barry Labinger, Chief Executive Officer. “Our recent public offering positions us well to execute on our clinical and strategic plans, including advancement of CMP-001 towards...

ATLANTA, Sept. 18, 2020 (GLOBE NEWSWIRE) — Cardlytics, Inc. (NASDAQ: CDLX), an advertising platform in banks’ digital channels, today announced the pricing of $200 million principal amount of 1.00% convertible senior notes due 2025 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Cardlytics also granted the initial purchasers of the notes an option to purchase up to an additional $30 million principal amount of notes. The sale of the notes is expected to close on September 22, 2020, subject to customary closing conditions.The notes will be general unsecured obligations of Cardlytics and will accrue interest payable semiannually in arrears on March 15 and September 15 of each year,...

SAN DIEGO, Sept. 18, 2020 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK: GTCH) (“GBT” or the “Company”), announced that together with its Joint Venture partner, Alpha EDA, LLC (“Alpha”), that it is now in the process of updating its Epsilon, IC (integrated circuit) reliability clean-by-construction program, preparing for advanced manufacturing nodes.As foundries are now offering advanced IC manufacturing processes, fabless customers will have to decide whether to design and manufacture their next microchips around the current stable process or to move to a different one at 5nm and the upcoming 3nm. As 7nm is stable and already in successful use by semiconductor companies, the path to further advanced nodes, like 3nm is still convoluted due to the fact that foundries are still working on its breakthroughs. In general,...

STAMFORD, Conn., Sept. 18, 2020 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has entered into a sponsored research agreement with Fred Hutchinson Cancer Research Center (Fred Hutch) to further explore the ability of SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat, to modulate B-cell maturation antigen (BCMA) and potentiate BCMA-targeting therapies, including radioimmunotherapies, in a variety of preclinical and patient-derived multiple myeloma models developed by researchers at Fred Hutch. Damian Green, M.D., Associate Member of the Clinical Research Division at Fred Hutch and Associate Professor at the University of Washington...

Singapore, Sept. 18, 2020 (GLOBE NEWSWIRE) — Moxian, Inc. (“Moxian” or the “Company”) (MOXC), an offline-to-online (O2O) social media services and Internet media marketing services provider, today announces it has received a letter from Nasdaq, stating that the Company has regained compliance on a listing rule regarding the market value of the Company’s listed securities.As previously disclosed, the Company has been notified that by Nasdaq that for the last 30 consecutive business days prior to March 20, 2020, the market value of the Company’s listed securities was less than $35 million, which did not meet the requirement for continued listing on The Nasdaq Capital Market (the “Market Value Rule”). In accordance with Nasdaq Listing Rules, Nasdaq provided the Company until September 16, 2020, to regain compliance with the Market Value...

Savosolar PlcCompany Announcement, Insider information    18 September 2020 at 12.15 p.m. (CEST)Savosolar resolved on a directed share issue without consideration to the Board membersThe Board of Directors of Savosolar Plc (”Savosolar”) has resolved on a directed share issue to be used as a part of the Board members’ remuneration in accordance with the resolution by the Annual General Meeting on 27 April 2020.The Annual General Meeting of the company held on 27 April 2020 resolved that the members of the Board of Directors be paid the following remuneration for the term that begins at the end of the Annual General Meeting and ends at the end of the next Annual General Meeting: EUR 21,600 for the Chairman of the Board and EUR 10,800 for each of the other members of the Board. Approximately 40 per cent of the remuneration to be paid to...